29/01/21 | European affairs | Press release
[2] Centres for Disease Control and Prevention (CDC) COVID-19 Response Team, Food and Drug Administration: Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine: United…
29/01/21 | European affairs | Press release
EMA’s human medicines committee (CHMP) has updated the product information for the COVID-19 vaccine Comirnaty to clarify its position on the interval between the first and second dose. The product…
29/01/21 | European affairs | Press release
Today EMA has released its first safety update on a COVID-19 vaccine – Comirnaty. It concludes that safety data collected on Comirnaty use in vaccination campaigns is consistent with the…
06/01/21 | European affairs | Press release
COVID-19 mRNA vaccine (nucleoside modified) 1. What is COVID-19 Vaccine Moderna and what is it used for? COVID-19 Vaccine Moderna is a vaccine for preventing coronavirus disease 2019 (COVID-19) in…
06/01/21 | European affairs | Press release
EMA has recommended granting a conditional marketing authorisation for COVID-19 Vaccine Moderna to prevent coronavirus disease 2019 (COVID-19) in people from 18 years of age. This is the second COVID-19…
31/12/20 | European affairs | Press release
EMA’s assessment of the COVID-19 vaccine being developed by AstraZeneca and Oxford University has been progressing over the past weeks. The Agency is currently assessing data on the vaccine as…
21/12/20 | European affairs | Press release
EMA has recommended granting a conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer, to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of age.…
16/12/20 | European affairs | Press release
EMA’s Human Medicines Committee (CHMP) and its experts have been working intensively over the past weeks to evaluate data submitted by BioNTech and Pfizer in the context of the conditional…
01/12/20 | European affairs | Press release
EMA’s human medicines committee (CHMP) has started a rolling review of Ad26.COV2.S, a COVID-19 vaccine from Janssen Vaccines & Prevention B.V. The CHMP’s decision to start the rolling review is…
01/12/20 | European affairs | Press release
EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 mRNA vaccine by Moderna Biotech Spain, S.L. (a subsidiary of Moderna, Inc.). The assessment of the vaccine…
01/12/20 | European affairs | Press release
EMA has received an application for conditional marketing authorisation (CMA) for BNT162b2, a COVID‑19 mRNA vaccine developed by BioNTech and Pfizer. The assessment of BNT162b2 will proceed under an accelerated…
27/11/20 | European affairs | Press release
The President of the Republic attends a luncheon hosted by the German Presidency of the EU, at Landmark Hotel, in Lefkosia.
26/10/20 | European affairs | Press release
The President of the Republic, Mr. Nicos Anastasiades, condemns the unethical verbal attack, with unacceptable in international practice and diplomacy phraseology, which is received by the President of France Mr. Emanuel Macron…
13/10/20 | European affairs | Press release
The President of the Republic, Mr Nicos Anastasiades, departs tomorrow for Brussels where he will participate in the European Council Summit on 15 and 16 October. At the Summit the…
12/10/20 | European affairs | Press release
The Minister of Foreign Affairs, Mr Nikos Christodoulides, participated in the Foreign Affairs Council of the EU, held today, 12 October 2020, in Luxembourg.
